All In Biotech

Drug Trial Radar · NCT04478279

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

125

Actual

Start

Jul 1, 2020

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Sapience TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

Conditions

  • Glioblastoma
  • Melanoma Stage IV
  • Breast Cancer
  • Prostate Cancer
  • Glioblastoma Multiforme
  • GBM
  • Brain Cancer
  • Metastatic Breast Cancer
  • Metastatic Melanoma
  • Metastatic Prostate Cancer
  • Melanoma Recurrent
  • Prostate Cancer Metastatic
  • Recurrent Glioblastoma
  • Newly Diagnosed Glioblastoma

Interventions

  • ST101Drug

    ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

  • TemozolomideDrug

    Temozolomide

  • RadiationRadiation

    Radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)Time frame: 20 months
  2. Adverse EventsTime frame: 20 months

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Northwestern Medicine Cancer Centers

    Warrenville, Illinois

  • START Midwest

    Grand Rapids, Michigan

  • Columbia University

    New York, New York

  • Duke University School of Medicine

    Durham, North Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Edinburgh Cancer Centre

    Edinburgh, United Kingdom

  • The Beaston West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • University of Leeds

    Leeds, United Kingdom

  • Sarah Cannon Research Institute UK

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.